[Possibilities of immune prevention of pyo-septic complications in cancer patients by granulocytic colony stimulating factors].
The study was carried out during the postoperative period in 75 patients with cancer of the esophagus and cardial portion of the stomach and 40 patients with lung cancer; 64 of these patients received immunoprophylactic treatment with neipogen, granulocytic colony-stimulating factor. Immune prevention resulted in a 2-fold decrease in the incidence and severity of pyoseptic and visceral complications and 1.5 times decrease in the duration of hospital treatment and mortality during the early postoperative period. Neipogen therapy was conductive to a 2-fold increase in the leukocyte count during the postoperative period in comparison with the control. The range of "safe" values of the major mediators of inflammations (TNF-alpha, IL-1, IL-8), characteristic of uneventful course of the postoperative period, was determined. About 75% pyoseptic complications were associated with mediator levels below this range. The levels of inflammation mediators in the patients treated with neipogen were within the safe range.
Nekhaev
I V
IV
Sviridova
S P
SP
Kiselevskiĭ
M V
MV
D000328:Adult; D002299:Cardia; D004938:Esophageal Neoplasms / Q000276:immunology / Q000601:surgery*; D005260:Female; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007249:Inflammation / Q000517:prevention & control*; D007958:Leukocyte Count; D008175:Lung Neoplasms / Q000276:immunology / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D008991:Monitoring, Physiologic; D011183:Postoperative Complications / Q000517:prevention & control*; D011994:Recombinant Proteins; D013274:Stomach Neoplasms / Q000276:immunology / Q000601:surgery*; D013492:Suppuration / Q000517:prevention & control*; D013997:Time Factors
D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D000069585:Filgrastim